

Published in final edited form as:

Neuroepidemiology. 2013 ; 40(1): 36–41. doi:10.1159/000341410.

Carotid Artery Stenosis as a Cause of Stroke

Matthew L. Flaherty, MD, Brett Kissela, MD, Jane C. Khoury, PhD, Kathleen Alwell, BSN, Charles J. Moomaw, PhD, Daniel Woo, MD, MS, Pooja Khatri, MD, Simona Ferioli, MD, Opeolu Adeoye, MD, Joseph P. Broderick, MD, and Dawn Kleindorfer, MD

Departments of Neurology (M.L.F., B.K., K.A., C.J.M., D.W., P.K., S.F., J.P.B., D.K.) and Emergency Medicine (O.A.), University of Cincinnati Academic Health Center, and Division of Biostatistics and Epidemiology (J.C.K.), Cincinnati Children's Hospital Medical Center.

Abstract

Background—Population-based studies have estimated that $\approx 15\%$ of ischemic strokes are caused by large vessel cerebrovascular disease. We determined the types of large vessel atherosclerosis responsible for ischemic strokes in a population-based stroke study.

Methods—Patients with first-ever or recurrent ischemic stroke in the Greater Cincinnati area were identified during 2005 at all local hospitals. Study physicians assigned ischemic stroke subtypes. Overall event rates and incidence rates for first-ever events were calculated and age, race, and sex-adjusted to the 2000 US population.

Results—There were 2204 ischemic strokes, including 365 strokes of large vessel subtype (16.6% of all ischemic strokes). Extracranial internal carotid artery stenosis was associated with 8.0% of all ischemic strokes, while extracranial internal carotid artery occlusion and intracranial atherosclerosis were each associated with 3.5% of strokes. The annual rate of first-ever and recurrent stroke attributed to extracranial internal carotid stenosis was 13.4 (11.4–15.4) per 100,000 persons. We conservatively estimate that $\approx 41,000$ strokes may be attributed to extracranial internal carotid artery stenosis annually in the United States.

Conclusions—Large vessel atherosclerosis is an important cause of stroke, with extracranial internal carotid artery stenosis significantly more common than extracranial internal carotid artery occlusion or intracranial atherosclerotic disease.

Keywords

carotid stenosis; carotid atherosclerosis; intracranial atherosclerosis; stroke; stroke etiology; epidemiology; carotid occlusion

Introduction

Large vessel atherosclerotic cerebrovascular disease is an important cause of stroke that produces a higher risk of early recurrent ischemia than any other stroke subtype.¹ Risk factors for large vessel disease also differ from other stroke subtypes.^{2,3} Importantly, for patients with stroke or TIA attributed to severe ($> 70\%$) extracranial internal carotid artery (ICA) stenosis, prompt revascularization with carotid endarterectomy produces a dramatic reduction in recurrent stroke risk.⁴

Corresponding Author: Matthew L. Flaherty, MD, Department of Neurology, University of Cincinnati Academic Health Center, 260 Stetson St., Room 2316, PO Box 670525, Cincinnati, OH, 45267-0525, Telephone (513) 558-6609. Fax (513) 558-4305. matthew.flaherty@uc.edu.

Statistical analyses were performed by Drs. Khoury and Moomaw.

Prior population-based studies have estimated that $\approx 15\%$ of ischemic strokes are caused by large vessel atherosclerosis.^{2, 5, 6} However, these studies have generally not distinguished between vessel stenosis and occlusion, anterior and posterior circulations, or extracranial and intracranial locations. We determined the types of large vessel atherosclerosis responsible for ischemic strokes in a large, population-based stroke study. We focused especially upon extracranial ICA stenosis because of the pronounced benefit of appropriate treatment for this stroke mechanism.

Methods

This study was undertaken as part of the Greater Cincinnati/Northern Kentucky Stroke Study (GCNKSS). The GCNKSS was funded by the National Institute of Neurological Disorders and Stroke. The institutional review board for each participating hospital system approved the GCNKSS study. Methods of the GCNKSS have been previously published.^{7, 8} In 2005, study nurses screened the medical records of all inpatients with primary or secondary stroke-related ICD-9 discharge diagnoses (430–436) from all acute-care hospitals in the study region. Patients with stroke not found by inpatient screening were ascertained by monitoring all stroke-related visits to hospital emergency departments (with the exception of Cincinnati Children's Hospital) and screening of coroner's cases. The GCNKSS also included monitoring of university and public health clinics as well as a sampling scheme of private outpatient physician offices and nursing homes.⁷ For this analysis only patients presenting to an emergency room or hospital were included. Residents of the five county GCNK region seek care almost exclusively at one of the metropolitan hospitals included in the study.⁹ Patients living outside of the five counties of interest were excluded by zip code of residence.

Study nurses performed chart abstraction for all potential cases. These abstracts were reviewed in detail by study physicians. Physicians assigned a stroke category and mechanism to each event based upon all available information, using criteria previously reported.^{6, 7} Subtyping of ischemic stroke cases was performed using criteria adapted from the Classification of Cerebrovascular Diseases III and epidemiologic studies in Rochester, Minnesota.^{6, 10–13} Large vessel etiology required $\geq 50\%$ stenosis or occlusion of the relevant vessel. For this analysis patients with appropriate large vessel disease who also had a cardiac source of embolism (e.g. atrial fibrillation) or a lacunar infarction were categorized as large vessel etiology because a) some previous studies of carotid endarterectomy have included patients with potential stroke mechanisms other than large vessel disease^{14, 15} and b) clinicians often recommend endarterectomy for patients with stroke in the territory of significant carotid atherosclerosis despite other potential stroke mechanisms. Vascular dissections and perioperative strokes were not included as large vessel etiology. Isolated occlusions of the carotid terminus, middle cerebral artery, anterior cerebral artery, basilar artery, and posterior cerebral arteries were not considered large vessel because of our inability to distinguish embolus from in situ thrombosis. Cases with stenosis of both the distal common carotid artery and proximal internal carotid artery were classified as internal carotid artery stenosis. Tandem lesions were categorized according to the judgment of an investigator (M.L.F.). For this analysis patients with symptoms lasting < 24 hours but with DWI MRI sequences positive for acute stroke were classified as stroke cases.

To estimate the total burden produced by large vessel disease, event rates including both first-ever and recurrent ischemic strokes were calculated and age, race, and sex-adjusted to the 2000 US population. Incidence rates were then recalculated including only patients with first-ever ischemic stroke. For the calculation of event and incidence rates, the entire population of the five GCNK counties was considered at risk. Denominator age-, race- and sex-specific population estimates for each study year were obtained from published census

data.¹⁶ We applied overall age, race-, sex-adjusted event rates to the population of the United States in 2010 to estimate the total number of strokes attributable to extracranial internal carotid artery stenosis and occlusion annually. Our rates and estimates were not adjusted for patients who did not have vascular imaging or patients with stroke treated only in the outpatient setting.

Results

There were 2096 patients with 2204 first or recurrent ischemic strokes identified. The distribution of vascular imaging is presented in Table 1. Among these cases 79% had cervical vascular imaging with carotid ultrasound, MR angiography, CT angiography, or conventional cerebral angiography. Slightly less than one-half of our patients had some form of intracranial vascular imaging. Imaging rates for cervical vessels did not differ between black and white patients (78% vs. 75%, $p=0.24$), however black patients were more likely to have intracranial vascular imaging (55% vs. 41%, $p<0.001$). Male patients were more likely to have imaging than female patients for both extracranial vessels (79% vs. 73%, $p<0.001$) and intracranial vessels (48% vs. 40%, $p<0.001$). There were 348 patients with 365 strokes determined to be of large vessel mechanism (16.6% of all ischemic strokes). Of these, 22 had symptoms lasting < 24 hours but positive DWI imaging on MRI. A breakdown of large vessel cases is presented in Table 2. There were 176 strokes attributed to extracranial ICA stenosis (8.0% of all strokes) and 78 strokes attributed to extracranial ICA occlusion (3.5% of all strokes). Intracranial large vessel atherosclerosis accounted for 78 cases (3.5% of all strokes). There were 10 patients with tandem lesions who were categorized with the vessel felt most likely to be causative. Among 365 strokes with large vessel mechanism, 21.1% also had a potential cardiac source of embolus and 4.9% had a lacunar phenotype. Incidence rates for stroke attributed to extracranial ICA disease are presented in Table 3. Supplemental table 3a presents rates after exclusion of cases with a potential cardiac source of embolus or lacunar phenotype. We conservatively estimate that $\approx 41,000$ strokes may be attributed to extracranial ICA stenosis and $\approx 18,000$ strokes attributed to extracranial ICA occlusion annually in the United States, based on a projected 2010 population of 308,000,000.

Discussion

Large vessel atherosclerotic disease is of great importance to clinicians caring for patients with stroke or TIA because of its frequent occurrence, high risk of causing early recurrent ischemia, and treatable nature. Extracranial ICA stenosis is especially notable in this regard, as large studies have demonstrated that prompt endarterectomy markedly reduces risk of recurrent stroke.⁴ Our study shows that extracranial ICA atherosclerosis is the most important cause of large vessel stroke. There has been appropriate interest in determining the best treatment for extracranial ICA stenosis, most notably with multiple trials comparing carotid endarterectomy to carotid artery stenting.^{17–20} Although we have documented that a substantial number of strokes are attributable to ICA stenosis, most patients with asymptomatic carotid stenosis do not subsequently have strokes. Thus, our data do not imply that all patients with asymptomatic carotid stenosis should undergo revascularization.

Stroke attributed to extracranial ICA occlusion occurs at approximately half the rate of stroke due to ICA stenosis. The recently completed “Carotid Occlusion Surgery Study” (COSS) failed to show a benefit for extracranial-intracranial bypass among patients with carotid occlusion judged at high risk of recurrent stroke by PET imaging.²¹ Patients with symptomatic intracranial large vessel stenosis are also known to be at high risk of recurrence. The SAMMPRIS Trial tested intracranial stenting plus medical management vs.

medical management alone and was closed early due to high peri-procedural risk of stroke or death in the stenting group.²² Long term follow-up of subjects in SAMMPRIS continues.

Our study has limitations. Twenty-one percent of patients evaluated in an emergency room or hospital for ischemic stroke did not have documented cervical vascular imaging. In some cases imaging may have been performed in the outpatient setting (which we could not ascertain); in other cases it may have been omitted due to the presence of another stroke mechanism (e.g. atrial fibrillation), a devastating stroke where no intervention was planned, patient preference, or physician oversight. Our imaging rate is comparable to or higher than other population-based studies^{2, 3, 23}. Extracranial imaging was considerably more common than intracranial imaging. Although this likely occurred for several reasons, the most important was practical: carotid revascularization is of proven benefit for high grade extracranial ICA stenosis, while there are no proven therapies for intracranial stenosis beyond standard medical management. The result is an underestimation of intracranial atherosclerosis as a stroke mechanism.

We found no difference in imaging rates of cervical vessels by race. Black patients were more likely to have intracranial imaging than whites. This may have occurred because of higher reported rates of intracranial atherosclerosis among blacks²⁴ or a higher percentage of black patients being hospitalized at tertiary or academic hospitals. Women were less likely than men to have imaging of cervical or intracranial vessels. While physician bias is one potential explanation, other factors such as alternative stroke mechanisms, patient age and premorbid status, and stroke severity may be relevant. Further analysis of this question is beyond the scope of this report.

Approximately 10–20% of ischemic stroke patients in our community are evaluated on an outpatient basis.⁸ They would not be captured in our data, but we have no reason to believe they have a significantly different balance of stroke mechanisms. We did not include TIAs (without diffusion restriction on MRI) in this analysis because estimating the true burden of TIA in a large community is very difficult. Patients with TIA caused by large vessel stenosis arguably have the most to gain from prompt evaluation and intervention to prevent a potentially devastating stroke.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Acknowledgments and funding

Supported by NINDS R-01-NS030678.

Disclosures:

Dr. Flaherty has served as a consultant to Boehringer-Ingelheim and on an advisory board for CSL Behring. He has provided medicolegal case review. He is Principal Investigator of an NIH funded study of intracerebral hemorrhage for which study drug is supplied by Novo Nordisk. He is funded by NINDS grants 2P50NS044283, R01NS030678, R01NS036695, R01NS042167, R01NS052220, R01NS044876 and 1U01NS069763.

Dr. Kissela has served on an advisory board for Allergan, in an unpaid advisor to NexStim, and has provided medicolegal case review. He is funded by NINDS grants R01NS30678, U01 NS041588 and NCRR grant UL1 RR026.

Dr. Khoury is funded by NIH grants R01 NS 30678, P50 NC 44283, R01 DK68463, R01 AR055563, R03CA142099, R01 AR056259, and R01 ES015517.

Ms. Alwell is funded by NINDS grants R01NS30678, K23NS049463 and R01ND039987.

Dr. Moomaw is funded by NINDS grants R01NS30678, R01NS036695, R01NS39512, U01NS069763, and K23NS049463.

Dr. Woo is funded by NINDS grants R01NS036695, U01NS069763, R01NS069208, R01NS030678 and R01NS039512.

Dr. Khatri has served as a consultant to Utsuko Pharmaceuticals. She has received book royalties from Informa Inc. She is Principal Investigator of NINDS K23NS059843 grant with PROACT II data provided by Abbott. She is on the Executive Committee of the IMS III Trial NINDS U01NS052220, for which drugs and devices are provided by EKOS, Concentric, Penumbra, and Genentech. She serves as local PI for the ALIAS Trial NIH/NINDS U01NS056975, the SAMMPRIS Trial NIH/NINDS U01 NS058728, and SPOTRIAS grant community core NIH/NINDS P50 NS044283.

Dr. Ferioli has no conflicts to report.

Dr. Adeoye has served as a consultant and speaker for Genentech and EKR Therapeutics. He is funded by NINDS grants 2P50NS044283, 5R01NS0678, 5U10NS058982, and 5U01NS062851.

Dr. Broderick has consulted for PhotoThera, Inc and Genentech and received speaking fees from Oakstone Medical Publishing. He is Principal Investigator of NIH funded trials for which drugs or devices are supplied by Genentech, EKOS Corporation, Concentric, Inc., Penumbra, and Johnson and Johnson. He is funded by NINDS grants 2P50NS044283, R01NS030678, R01NS036695, R01NS044876, 5U01NS052220, and R01NS39512.

Dr. Kleindorfer serves on an advisory board for Boehringer Ingelheim, serves on a speaker's bureau for Genentech, and has provided medicolegal case review. She is funded by NINDS grants R01NS30678 and K23NS049463 and from the CDC MM-0971-07/07.

References

1. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in populationbased studies. *Neurology*. 2004; 62:569–573. [PubMed: 14981172]
2. Petty GW, Brown RD Jr, Whisnant JP, et al. Ischemic stroke subtypes: A population-based study of incidence and risk factors. *Stroke*. 1999; 30:2513–2516. [PubMed: 10582970]
3. Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Incidence, recurrence, and long term survival in ischemic stroke subtypes: A population-based study. *Stroke*. 2001; 32:2735–2740. [PubMed: 11739965]
4. Rothwell PM, Eliasziw M, Gutnikov SA, et al. for the Carotid Endarterectomy Trialists' Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. *Lancet*. 2003; 361:107–116. [PubMed: 12531577]
5. Uchino K, Risser JMH, Smith MA, et al. Ischemic stroke subtypes among Mexican Americans and non-Hispanic whites: The BASIC project. *Neurology*. 2004; 63:574–576. [PubMed: 15304600]
6. Schneider AT, Kissela B, Woo D, et al. Ischemic stroke subtypes: A population-based study of incidence rates among blacks and whites. *Stroke*. 2004; 35:1552–1556. [PubMed: 15155974]
7. Kissela B, Schneider A, Kleindorfer D, et al. Stroke in a biracial population: The excess burden of stroke among blacks. *Stroke*. 2004; 35:426–431. [PubMed: 14757893]
8. Kleindorfer D, Broderick J, Khoury J, et al. The unchanging incidence and case-fatality of stroke in the 1990s: A population-based study. *Stroke*. 2006; 37:2473–2478. [PubMed: 16946146]
9. Broderick JP, Brott T, Tomsick T, et al. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. *NEJM*. 1992; 326:733–736. [PubMed: 1738378]
10. National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. *Stroke*. 1990; 21:637–676. [PubMed: 2326846]
11. Broderick JP, Phillips SJ, O'Fallon WM, et al. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. *Stroke*. 1992; 23:1250–1256. [PubMed: 1519279]
12. Sacco SE, Whisnant JP, Broderick JP, et al. Epidemiological characteristics of lacunar infarcts in a population. *Stroke*. 1991; 22:1236–1241. [PubMed: 1926233]
13. Flaherty ML, Kleindorfer D, Alwell K, et al. Did more testing lead to fewer cryptogenic strokes during the 1990s? *Stroke*. 2006; 37:649. Abstract.

14. Howard VJ, Grizzle J, Diener HC, et al. Comparison of multicenter study designs or investigation of carotid endarterectomy efficacy. *Stroke*. 1992; 23:583–593. [PubMed: 1561692]
15. Inzitari D, Eliasziw M, Sharpe BL, et al. Risk factors and outcome of patients with carotid artery stenosis presenting with lacunar stroke. *Neurology*. 2000; 54:660–666. [PubMed: 10680800]
16. [Accessed May 18, 2011] US Census Bureau website. http://factfinder.census.gov/servlet/DTTable?_bm=y&-geo_id=01000US&-ds_name=DEC_2000_SF1_U&-_lang=en&-state=dt&-mt_name=DEC_2000_SF1_U_P012A&-mt_name=DEC_2000_SF1_U_P012B&-mt_name=DEC_2000_SF1_U_P012C&-mt_name=DEC_2000_SF1_U_P012D&-mt_name=DEC_2000_SF1_U_P012E&-mt_name=DEC_2000_SF1_U_P012F&-mt_name=DEC_2000_SF1_U_P012G&-mt_name=DEC_2000_SF1_U_P012H&-mt_name=DEC_2000_SF1_U_P012I&-format=&-CONTEXT=dt.
17. Eckstein H-H, Ringleb P, Allenberg J-R, et al. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) Study to treat symptomatic stenoses at 2 years: A multinational, prospective, randomised trial. *Lancet Neurol*. 2008; 7:893–902. [PubMed: 18774746]
18. Mas J-L, Trinquart L, Leys D, Albucher J-F, et al. for the EVA-3S Investigators. Endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis (EVA-3S) trial: Results up to 4 years from a randomised, multicentre trial. *Lancet Neurol*. 2008; 7:885–892. [PubMed: 18774745]
19. International Carotid Stenting Study Investigators. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): An interim analysis of a randomised controlled trial. *Lancet*. 2010; 375:985–997. [PubMed: 20189239]
20. Brott TG, Hobson RW II, Howard G, et al. for the CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. *NEJM*. 2010; 363:11–23. [PubMed: 20505173]
21. Powers WJ, Clarke WR, Grubb RL, et al. for the COSS Investigators. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia. The Carotid Occlusion Surgery Study randomized trial. *JAMA*. 2011; 306:1983–1992. [PubMed: 22068990]
22. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. *NEJM*. 2011; 365:993–1003. [PubMed: 21899409]
23. Smith MA, Lisabeth LD, Brown DL, et al. Gender comparisons of diagnostic evaluation for ischemic stroke patients. *Neurology*. 2005; 65:855–858. [PubMed: 16186523]
24. Sacco RL, Kargman DE, Qiong G, et al. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction: The Northern Manhattan Stroke Study. *Stroke*. 1995; 26:14–20. [PubMed: 7839388]

Table 1

Vascular imaging rates by modality and anatomic site.

	Carotid ultrasound	MRA neck	MRA head	CTA neck	CTA head	Cerebral angiogram	Any imaging neck	Any imaging head
All strokes	1200 (54%)	724 (33%)	918 (42%)	25 (1%)	21 (1%)	76 (3%)	1661 (79%)	966 (44%)
n=2204								
White *	993 (58%)	506 (29%)	656 (38%)	22 (1%)	18 (1%)	59 (3%)	1286 (75%)	696 (41%)
n=1716								
Black *	200 (42%)	212 (44%)	225 (53%)	3 (1%)	3 (1%)	17 (4%)	370 (78%)	263 (55%)
n=477								
Male	551 (56%)	370 (37%)	453 (46%)	15 (2%)	13 (1%)	33 (3%)	781 (79%)	480 (48%)
n=989								
Female	649 (53%)	354 (29%)	465 (38%)	10 (1%)	8 (1%)	43 (4%)	885 (73%)	486 (40%)
n=1215								

MRA = magnetic resonance angiography; CTA = computed tomographic angiography

* There were 11 additional subjects not of black or white race.

Table 2

Breakdown of large vessel stroke cases by location and pathology.

Large vessel ischemic stroke n=365*								
Extracranial large vessel n=287			Intracranial large vessel n=78					
Stenosis n=190		Occlusion n=97	Stenosis n=66		Occlusion n=12			
Cases	% of all strokes [†]	Cases	% of all strokes [†]	Cases	% of all strokes [†]	Cases	% of all strokes [†]	
ICA	176	8.0%	78	3.5%	19	0.9%	4	0.2%
CCA			1	0.04%				
Vertebral	14	0.6%	18	0.8%	6	0.3%	8	0.4%
Artery								
MCA					21	1.0%	7	7
ACA							7	7
Basilar					10	0.4%	7	7
Artery								
PCA					10	0.4%	7	7

ICA = internal carotid artery; CCA = common carotid artery; MCA = middle cerebral artery; ACA = anterior cerebral artery; PCA = posterior cerebral artery

* Including 15 patients with two large vessel strokes and one patient with three large vessel strokes during the study period.

[†] Percent of all ischemic strokes (n=2204) of any mechanism

[‡] Isolated occlusions of the middle cerebral, anterior cerebral, basilar, and posterior cerebral arteries were not classified as large vessel etiology due to the inability to distinguish embolic occlusion from in situ thrombosis.

Table 3

Event rates for stroke attributed to extracranial internal carotid artery stenosis and occlusion *

	Stenosis		Occlusion	
	First-ever events	First-ever and recurrent events	First-ever events	First-ever and recurrent events
All	n=140 10.7 (8.9, 12.5)	n=176 13.4 (11.4, 15.4)	n=48 3.7 (2.6, 4.8)	n=78 6.0 (4.6, 7.3)
Male	n=70 13.3 (10.1, 16.4)	n=87 16.5 (13.0, 20.0)	n=26 4.7 (2.8, 6.5) ^	n=45 7.8 (5.5, 10.1)
Female	n=70 8.8 (6.7, 10.9)	n=89 11.3 (8.9, 13.7)	n=22 2.9 (1.7, 4.1) ^	n=33 4.4 (2.9, 5.9)
White	n=123 10.8 (8.9, 12.7)	n=153 13.4 (11.3, 15.6)	n=43 3.8 (2.7, 5.0)	n=67 6.0 (4.6, 7.4)
Black	n=17 10.2 (5.3, 15.0) ^	n=23 13.6 (8.0, 19.2) ^	n=5 2.8 (0.3, 5.3) ^	n=11 6.1 (2.4, 9.7) ^

* Rate per 100,000 persons per year, adjusted to the 2000 United States population.

^ Small cell sizes (< 30) may produce unstable estimates.